{"organizations": [], "uuid": "51aad35e24214bb5f9e95217c34a0199070c855e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "au.finance.yahoo.com", "main_image": "https://s1.yimg.com/bt/api/res/1.2/24bolFypzro61Gai__8DDg--/YXBwaWQ9eW5ld3NfbGVnbztpbD1wbGFuZTtxPTc1O3c9NjAw/http://globalfinance.zenfs.com/images/FIN_ANZ_AAP_ART_FTP_LIVE_1/3082803_20131016000810582329-original_1280x720_original.jpg", "site_section": "https://au.finance.yahoo.com/news/topic-top-stories/?format=rss", "section_title": "Australian Business & World Finance News - Yahoo!7 Finance", "url": "https://au.finance.yahoo.com/news/back-back-buybacks-csl-040903006.html", "country": "GB", "title": "Back-to-back buybacks for CSL", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "Back-to-back buybacks for CSL", "spam_score": 0.0, "site_type": "news", "published": "2015-10-15T07:09:00.000+03:00", "replies_count": 0, "uuid": "51aad35e24214bb5f9e95217c34a0199070c855e"}, "author": "", "url": "https://au.finance.yahoo.com/news/back-back-buybacks-csl-040903006.html", "ord_in_thread": 0, "title": "Back-to-back buybacks for CSL", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "View Photo \n\nBlood products and flu vaccines supplier CSL has announced its biggest ever share buyback, just 12 months after the last one. \nCSL, whose share price touched $100 earlier this year for the second time in the company's history, will buy back up to $1 billion of its shares over the next year. \nIn June, CSL completed a $950 million share buyback that was announced in October 2014. \nAt Wednesday's closing price of $89.25 for CSL shares, the latest buyback represents about 11.2 million shares, or around 2.4 per cent of the company's stock. \nIt is CSL's ninth buyback in the past decade. \nThe company has bought back 23 per cent of its shares in that time, returning $5.16 billion to shareholders. \n\"Our ability to undertake another buyback of this scale is testament to CSL's strong financial position and excellent cashflow,\" chairman John Shine told shareholders at the company's annual general meeting on Thursday. \nProfessor Shine also said that growth in CSL's earnings per share in the 2015/16 financial year would exceed profit growth expectations as shareholders benefit from the ongoing effect of past and current buybacks. \nMeanwhile chief executive Paul Perreault says CSL's integration of the Novartis flu business is proceeding well. \nCSL acquired the business in July 2015, which, combined with CSL's existing flu division, makes CSL the second biggest flu vaccines supplier in the world. \n\"It (the Novartis flu integration) is going great,\" Mr Perreault told reporters after the meeting. \nHe said the management team for the business was coming together well, and the integration team was working hard to identify the efficiencies and savings that will make the business profitable over time. \nCSL expects the Novartis flu business to break even this financial year, post a loss next year, and then start to return to profitability. \nMr Perreault said the first priority for the flu business - to be renamed Seqirus - is to establish a UK head office at Maidenhead, near London. \nCSL will also move to get more value from the capability and products at the Novartis cell culture vaccine facility at Holly Springs, North Carolina. \nCSL on Thursday affirmed its financial guidance for the current financial year. \nExcluding the impact of the Novartis acquisition, CSL expects to lift its net profit by around five per cent on a constant currency basis. \nProfessor Shine said that at the end of the first quarter, CSL was trading consistently with the company's expectations. \n\"While the markets in which we operate remain highly competitive, our broad portfolio of innovative products, ongoing product development and growing demographic reach continue to ensure our business remains well positioned,\" Prof Shine said. \nCSL shares were three cents higher at $89.28 at 1427 AEDT. @y7finance on Twitter, become a fan on Facebook Back-to-back buybacks for CSL AAP \nIn June, CSL completed a $950 million share buyback that was announced in October 2014. At Wednesday's closing â€¦", "external_links": [], "published": "2015-10-15T07:09:00.000+03:00", "crawled": "2015-10-15T08:05:53.811+03:00", "highlightTitle": ""}